Nesfatin-1 protects against diabetic cardiomyopathy in the streptozotocin-induced diabetic mouse model via the p38-MAPK pathway

References

• Kaul K, Tarr JM, Ahmad SI, et al. Introduction to diabetes mellitus. Adv Exp Med Biol. 2012;771:1–11.
   PubMed Web of Science ®Google Scholar
• Vassort G, Turan B. Protective role of antioxidants in diabetes-induced cardiac dysfunction. Cardiovasc Toxicol. 2010;10(2):73–86.
   PubMedGoogle Scholar
• Park S, Kang HJ, Jeon JH, et al. Recent advances in the pathogenesis of microvascular complications in diabetes. Arch Pharm Res. 2019;42(3):252–262.
   PubMed Web of Science ®Google Scholar
• Dillmann WH. Diabetic Cardiomyopathy. Circ Res. 2019;124(8):1160–1162.
   PubMed Web of Science ®Google Scholar
• Ayada C, Toru U, Korkut Y. Nesfatin-1 and its effects on different systems. Hippokratia. 2015;19(1):4–10.
   PubMed Web of Science ®Google Scholar
• Dore R, Levata L, Lehnert H, et al. Nesfatin-1: functions and physiology of a novel regulatory peptide. J Endocrinol. 2017;232(1):R45–R65.
   PubMed Web of Science ®Google Scholar
• Gonzalez R, Reingold BK, Gao X, et al. Nesfatin-1 exerts a direct, glucose-dependent insulinotropic action on mouse islet beta- and MIN6 cells. J Endocrinol. 2011;208(3):R9–R16.
   PubMed Web of Science ®Google Scholar
• Ozturk Ozkan G. Effects of Nesfatin-1 on Food Intake and Hyperglycemia. J Am Coll Nutr. 2020;39(4):345–351.
   PubMed Web of Science ®Google Scholar
• Ranjan A, Choubey M, Yada T, et al. Nesfatin-1 ameliorates type-2 diabetes-associated reproductive dysfunction in male mice. J Endocrinol Invest. 2020;43(4):515–528.
   PubMed Web of Science ®Google Scholar
• Ramesh N, Gawli K, Pasupulleti VK, et al. Metabolic and Cardiovascular Actions of Nesfatin-1. Implications in Health and Disease, Curr Pharm Des. 2017;23(10):1453–1464
   PubMed Web of Science ®Google Scholar
• Feijoo-Bandin S, Rodriguez-Penas D, Garcia-Rua V, et al. Nesfatin-1: a new energy-regulating peptide with pleiotropic functions. Implications at cardiovascular level, Endocrine. 2016;52:11–29.
   Google Scholar
• Erfani S, Moghimi A, Aboutaleb N, et al. Protective Effects of Nuclear binding-2 After Cerebral Ischemia Via Modulating Bcl-2/Bax Ratio and Reducing Glial Fibrillary Acid Protein Expression. Basic Clin Neurosci. 2019;10(5):451–459.
   PubMed Web of Science ®Google Scholar
• Yan L, Li HJ, An WB, et al. Mex-3 RNA binding MEX3A promotes the proliferation and migration of breast cancer cells via regulating RhoA/ROCK1/LIMK1 signaling pathway. Bioengineered. 2021;12(1):5850–5858.
   PubMed Web of Science ®Google Scholar
• Wang XD, Zhang CH, Zou N, et al. Lipocalin-2 silencing suppresses inflammation and oxidative stress of acute respiratory distress syndrome by ferroptosis via inhibition of MAPK/ERK pathway in neonatal mice. Bioengineered. 2022;13(1):508–520.
   PubMed Web of Science ®Google Scholar
• Goldberg RB. Hyperlipidemia and cardiovascular risk factors in patients with type 2 diabetes. Am J Manag Care. 2000;6(13 Suppl):S682–691. discussion S692-686.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Pathophysiology of type 2 diabetes. Acta Clin Belg. 2003;58(6):335–341.
   PubMed Web of Science ®Google Scholar
• Jia G, DeMarco VG, Sowers JR. Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy. Nat Rev Endocrinol. 2016;12(3):144–153.
   PubMed Web of Science ®Google Scholar
• Nowotny K, Jung T, Hohn A, et al. Advanced glycation end products and oxidative stress in type 2 diabetes mellitus. Biomolecules. 2015;5(1):194–222.
   PubMed Web of Science ®Google Scholar
• Papachristoforou E, Lambadiari V, Maratou E, et al. Association of Glycemic Indices (Hyperglycemia, Glucose Variability, and Hypoglycemia) with Oxidative Stress and Diabetic Complications. J Diabetes Res. 2020;2020:7489795.
   PubMed Web of Science ®Google Scholar
• Giacco F, Brownlee M, Schmidt AM. Oxidative stress and diabetic complications. Circ Res. 2010;107(9):1058–1070.
   PubMed Web of Science ®Google Scholar
• Bodiga VL, Eda SR, Bodiga S. Advanced glycation end products: role in pathology of diabetic cardiomyopathy. Heart Fail Rev. 2014;19(1):49–63.
   PubMed Web of Science ®Google Scholar
• Russo I, Frangogiannis NG. Diabetes-associated cardiac fibrosis: cellular effectors, molecular mechanisms and therapeutic opportunities. J Mol Cell Cardiol. 2016;90:84–93.
   PubMed Web of Science ®Google Scholar
• Pappachan JM, Varughese GI, Sriraman R, et al. Diabetic cardiomyopathy: pathophysiology, diagnostic evaluation and management. World J Diabetes. 2013;4(5):177–189.
   PubMedGoogle Scholar
• Ma H, Li S-Y, Xu P, et al. Advanced glycation endproduct (AGE) accumulation and AGE receptor (RAGE) up-regulation contribute to the onset of diabetic cardiomyopathy. J Cell Mol Med. 2009;13(8b):1751–1764.
   PubMed Web of Science ®Google Scholar
• Sies H. Oxidative stress: a concept in redox biology and medicine. Redox Biol. 2015;4:180–183.
   PubMed Web of Science ®Google Scholar
• Peoples JN, Saraf A, Ghazal N, et al. Mitochondrial dysfunction and oxidative stress in heart disease. Exp Mol Med. 2019;51(12):1–13.
   PubMedGoogle Scholar
• Tsutsui H, Kinugawa S, Matsushima S. Oxidative stress and heart failure. Am J Physiol Heart Circ Physiol. 2011;301(6):H2181–2190.
   PubMed Web of Science ®Google Scholar
• Kenny HC, Abel ED. Heart Failure in Type 2 Diabetes Mellitus. Circ Res. 2019;124(1):121–141.
   PubMed Web of Science ®Google Scholar
• Kay AM, Simpson CL, Stewart JA Jr. The Role of AGE/RAGE Signaling in Diabetes-Mediated Vascular Calcification. J Diabetes Res. 2016;2016:6809703.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Han Z, Zhao H, et al. MAPK: a Key Player in the Development and Progression of Stroke. CNS Neurol Disord Drug Targets. 2020;19(4):248–256.
   PubMed Web of Science ®Google Scholar
• Wang S, Ding L, Ji H, et al. The Role of p38-MAPK in the Development of Diabetic Cardiomyopathy. Int J Mol Sci. 2016;17(7):1037.
   Web of Science ®Google Scholar
• Li M, Li K, Ren Y. Nesfatin-1 protects H9c2 cardiomyocytes against cobalt chloride-induced hypoxic injury by modulating the MAPK and Notch1 signaling pathways. J Biol Res (Thessalon). 2021;28(1):21.
   PubMed Web of Science ®Google Scholar
• Rupp SK, Wölk E, Stengel A. Nesfatin-1 Receptor: distribution, Signaling and Increasing Evidence for a G Protein-Coupled Receptor - A Systematic Review. Front Endocrinol (Lausanne). 2021;12:740174.
   PubMed Web of Science ®Google Scholar